• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Nemaura Medical Inc.

    2/14/24 1:54:39 PM ET
    $NMRD
    Medical/Dental Instruments
    Health Care
    Get the next $NMRD alert in real time by email
    SC 13G 1 alyeska-nmrd123123.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*



    Nemaura Medical Inc.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    640442208

    (CUSIP Number)

     

     

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  640442208
     SCHEDULE 13G
    Page 2 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Alyeska Investment Group, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,887,050
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,887,050
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,887,050
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99% *
    12
    TYPE OF REPORTING PERSON
     
    IA

    The reporting persons are the beneficial owners of 2,887,050 shares of Common Stock of the Issuer, which constitute approximately 9.99% of the Issuer’s outstanding Common Stock shares. The percentage calculation assumes that there are currently 28,899,402 outstanding shares of Common Stock of the Issuer, based on the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 13, 2023.

     


     

    CUSIP No.  640442208
     SCHEDULE 13G
    Page 3 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Alyeska Fund GP, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,887,050
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,887,050
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,887,050
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99%*
    12
    TYPE OF REPORTING PERSON
     
    OO

    The reporting persons are the beneficial owners of 2,887,050 shares of Common Stock of the Issuer, which constitute approximately 9.99% of the Issuer’s outstanding Common Stock shares. The percentage calculation assumes that there are currently 28,899,402 outstanding shares of Common Stock of the Issuer, based on the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 13, 2023.

     


     

    CUSIP No.  640442208
     SCHEDULE 13G
    Page 4 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Anand Parekh
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States of America
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,887,050
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,887,050
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,887,050
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99%
    12
    TYPE OF REPORTING PERSON
     
    IN
    The reporting persons are the beneficial owners of 2,887,050 shares of Common Stock of the Issuer, which constitute approximately 9.99% of the Issuer’s outstanding Common Stock shares. The percentage calculation assumes that there are currently 28,899,402 outstanding shares of Common Stock of the Issuer, based on the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 13, 2023.
     


     

     

    CUSIP No. 640442208
     SCHEDULE 13G
    Page 5 of 9 Pages

     

    Item 1.(a) Name of Issuer

    Nemaura Medical Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    57 West 57th Street

    Manhattan, NY 10019

    Item 2.(a) Names of Person Filing:

    (i) Alyeska Investment Group, L.P.

     

    (ii) Alyeska Fund GP, LLC

     

    (iii) Anand Parekh

      

    Item 2.(b) Address of Principal Business Office:

    (i) 77 West Wacker Drive, 7th Floor

    Chicago, IL 60601

     

    (ii) 77 West Wacker Drive, 7th Floor

    Chicago, IL 60601

     

    (iii) 77 West Wacker Drive, 7th Floor

    Chicago, IL 60601

      

    Item 2.(c) Citizenship:

    (i) Alyeska Investment Group, L.P. - Delaware

     

    (ii) Alyeska Fund GP, LLC - Delaware

     

    (iii) Anand Parekh - United States of America

      

    Item 2.(d) Title of Class of Securities

    Common Stock

     

    Item 2.(e) CUSIP No.:

    640442208

     

    CUSIP No.  640442208
     SCHEDULE 13G
    Page 6 of 9 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 640442208
     SCHEDULE 13G
    Page 7 of 9 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned: Please refer to items 5-9 of the cover pages attached hereto

    (b) Percent of class: Please refer to item 11 of the cover pages attached hereto

    (c) Number of shares as to which the person has: Please refer to items 5-8 of the cover pages attached hereto

    The reporting persons are the beneficial owners of 845,060 shares of Common Stock of the Issuer and hold warrants to purchase 2,398,103 shares of the Issuer’s Common Stock (the “Warrants”).  However, per their terms, the Warrants can only be exercised into such number of shares that would constitute 9.9% of the total number of Common Stock of the Issuer outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant by the Holder.  Accordingly, as of December 31, 2023 the reporting persons may only exercise up to 2,041,990 shares of Common Stock under the Warrant Agreement, and as such, is reporting beneficial ownership of only such number of shares.  The percentage calculation assumes that there are currently 28,899,402 outstanding shares of Common Stock of the Issuer, based on the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 13, 2023.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 640442208
     SCHEDULE 13G
    Page 8 of 9 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

     

     

     

     

    Alyeska Investment Group, L.P.

           
      By:  /s/ Jason Bragg
        Jason Bragg, Chief Financial Officer
           
     

    Alyeska Fund GP, LLC

           
      By:  /s/ Jason Bragg
        Jason Bragg, Chief Financial Officer
     

     

    Anand Parekh

    By:  Entity and Description

           
      By:  /s/ Anand Parekh
        Anand Parekh, Individually
           

     

     
    CUSIP No. 640442208
     SCHEDULE 13G
    Page 9 of 9 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: February 14, 2024

     

     

    Alyeska Investment Group, L.P.

           
      By:  /s/ Jason Bragg
        Jason Bragg, Chief Financial Officer
           
     

    Alyeska Fund GP, LLC

           
      By:  /s/ Jason Bragg
        Jason Bragg, Chief Financial Officer
     

     

    Anand Parekh

           
      By:  /s/ Anand Parekh
        Anand Parekh, Individually
           
    Get the next $NMRD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NMRD

    DatePrice TargetRatingAnalyst
    3/29/2022$12.00Buy
    H.C. Wainwright
    12/2/2021$7.50Buy
    EF Hutton
    More analyst ratings

    $NMRD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ghadar-Ghadr Arash bought $14,000 worth of shares (100,000 units at $0.14) (SEC Form 4)

      4 - Nemaura Medical Inc. (0001602078) (Issuer)

      1/9/24 5:30:57 PM ET
      $NMRD
      Medical/Dental Instruments
      Health Care

    $NMRD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Nemaura Medical with a new price target

      H.C. Wainwright initiated coverage of Nemaura Medical with a rating of Buy and set a new price target of $12.00

      3/29/22 7:19:31 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care
    • EF Hutton initiated coverage on Nemaura Medical with a new price target

      EF Hutton initiated coverage of Nemaura Medical with a rating of Buy and set a new price target of $7.50

      12/2/21 8:50:25 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care

    $NMRD
    Leadership Updates

    Live Leadership Updates

    See more
    • Nemaura Medical Announces Appointment of Mr Nikolai Rozanov as Strategic Adviser in Artificial Intelligence, to Assist in Development of its AI Health Coach, and Strengthen Outcomes in its CGM Based Metabolic and Type 2 Diabetes Programs.

      LOUGHBOROUGH, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the appointment of Nikolai Rozanov as strategic adviser in AI development. Mr Rozanov is a specialist in the field of artificial intelligence and was selected for inclusion by Forbes magazine in their '30 Under 30' list in the field of technology, a prestigious honour accorded to the best up-and-coming talent in the sector. The appointment of Mr Rozanov solidifies the Company's expertise in

      9/26/23 9:50:00 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care
    • Nemaura Medical Appoints Dr. Arash Ghadar as Chief Operating Officer

      Loughborough, England, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ:NMRD)("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces the appointment of Dr. Arash (Ash) Ghadar as Chief Operating Officer. "Ash will play an important role at Nemaura as we begin to scale up our manufacturing and distribution operations. He brings over 20 years of product development, management and leadership experience spanning both business and technical disciplines. His main area of expertise is in the medical devices sector, and primarily w

      1/10/22 8:00:00 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care
    • Nemaura Medical Appoints Samantha Sanders as Global Head of Digital Programs

      Loughborough, England, April 15, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the appointment of Samantha Sanders as its Global Head of Digital Programs. Samantha has over two decades of project development, management and customer service experience, delivering successful digital projects to market within the wellbeing, pharmaceutical and medical device sector, both locally and internationally.  Prior to joining the Nemaura team, more recently Samantha has bee

      4/15/21 8:07:00 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care

    $NMRD
    Financials

    Live finance-specific insights

    See more
    • Nemaura Medical, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

      ORLANDO, FL / ACCESSWIRE / November 4, 2022 / RedChip Companies will air a new interview with Nemaura Medical, Inc. (NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, on The RedChip Money Report® on Bloomberg TV, this Saturday, November 5, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Interview highlights:In the exclusive RedChip Money Report interview, Nemaura's CEO Dr. Faz Chowdhury discusses Nemaura's continuous glucose sensor, the sugarBEAT®, its potential impact on the 500

      11/4/22 8:00:00 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care
    • Nemaura Medical Reports Financial Results and Provides Business Update for the Fiscal Year Ended March 31, 2022

      Loughborough, England, June 30, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today provides a business update and releases its financial results for the fiscal year ended March 31, 2022. Corporate Highlights for FY2022: Commenced shipments of sugarBEAT® continuous glucose monitor (CGM) devices to its UK licensee, MySugarWatch Limited ("MSWL"), previously DB Ethitronix Limited. MSWL commenced mass educational and awareness campaigns to physicians in the UK via a

      6/30/22 8:00:00 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care
    • Nemaura Medical Reports Financial Results and Provides Business Update for the First Fiscal Quarter Ended June 30, 2021

      Loughborough, England, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today provides a business update and releases its financial results for the first fiscal quarter, ended June 30, 2021, of fiscal 2022. Recent Corporate Highlights: Launched a digital healthcare subscription service in the U.S. under the brand name BEAT®diabetes, targeted at over 25 million people with Type 2 diabetes and 88 million people with pre-diabetes in the U.S.Received positive feedback fro

      8/16/21 8:30:00 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care

    $NMRD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CRAIG D. LINDER SELECTED TO 2024 TOP 50 LAWYERS IN AMERICA

      WEST PALM BEACH, Fla., April 11, 2024 /PRNewswire/ --   Anthony, Linder & Cacomanolis, PLLC is proud to announce that Partner Craig D. Linder has been selected to the 2024 Top 50 Lawyers in America list for securities law. This prestigious accolade is part of the 10th annual list honoring a select group of 50 lawyers who have demonstrated outstanding leadership and success within the securities law community in the Americas. America's Top 50 Lawyers identifies and highlights the accomplishments of the nation's most distinguished and skilled attorneys in all fields of practice of law. Only 50 lawyers in each state will receive this honor and be selected for this esteemed membership. This hon

      4/11/24 10:00:00 AM ET
      $FUBO
      $HOUR
      $HTCR
      $MOBQ
      Movies/Entertainment
      Consumer Discretionary
      Catalog/Specialty Distribution
      EDP Services
    • Important Update on Listing Status and Strategic Direction

      Loughborough, UK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. ("Nemaura Medical" or the "Company"), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs, is providing a crucial update regarding recent decisions that will impact Nemaura Medical's listing status on The Nasdaq Capital Market and our broader strategic direction. Background: After thorough analysis, Nemaura Medical's Board of Directors and management team have made the strategic decision to accept Nasdaq's determination to delist Nemaura Medical and move to the OTC Markets. This decision arises from a careful consideration of several factors, including challenges outside of our cont

      1/3/24 7:00:00 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care
    • Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision

      Loughborough, UK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ:NMRD) ("Nemaura Medical" or the "Company"), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce that the Nasdaq Hearings Panel granted the Company's request for continued listing pursuant to an exception, including certain interim milestones, that ultimately expires on April 1st, 2024, to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market. The Company plans to continue with its commercial endeavours while pursuing its plans to ensure timely compliance with the terms of the Nasdaq Hearing Panel's decision

      12/13/23 8:00:00 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care

    $NMRD
    SEC Filings

    See more
    • Nemaura Medical Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Nemaura Medical Inc. (0001602078) (Filer)

      9/26/24 9:21:38 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14C filed by Nemaura Medical Inc.

      DEF 14C - Nemaura Medical Inc. (0001602078) (Filer)

      7/1/24 7:59:03 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care
    • SEC Form NT 10-K filed by Nemaura Medical Inc.

      NT 10-K - Nemaura Medical Inc. (0001602078) (Filer)

      7/1/24 7:00:02 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care

    $NMRD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $NMRD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Ghadar-Ghadr Arash bought $14,000 worth of shares (100,000 units at $0.14) (SEC Form 4)

      4 - Nemaura Medical Inc. (0001602078) (Issuer)

      1/9/24 5:30:57 PM ET
      $NMRD
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Ghadar-Ghadr Arash

      3 - Nemaura Medical Inc. (0001602078) (Issuer)

      1/9/24 5:29:16 PM ET
      $NMRD
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Natha Salim

      4 - Nemaura Medical Inc. (0001602078) (Issuer)

      2/1/22 4:13:05 PM ET
      $NMRD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Nemaura Medical Inc.

      SC 13G - Nemaura Medical Inc. (0001602078) (Subject)

      2/14/24 1:54:39 PM ET
      $NMRD
      Medical/Dental Instruments
      Health Care